日本 ppt Japan_ Rapidly developing novel drugs for cardiovascular and infectious diseases概要1.pptVIP

June 2003 VDDI Pharmaceuticals (Asia Pacific) CONFIDENTIAL VDDI Pharmaceuticals “Rapidly developing novel drugs for cardiovascular and infectious diseases” William Porter Senior Vice President Business Development, Asia-Pacific VDDI Pharmaceuticals Inc. Brentwood, TN USA June 2003 Bangkok, Thailand + 661 802-9244 (cell) email: virtual@loxinfo.co.th The material and comments in this presentation is confidential, proprietary?and privileged, including copyright. Statements made in this presentation are based on information available to VDDI, and are presented in the good faith belief as to their accuracy, but VDDI does not warrant their accuracy. VDDI Virtual Drug Development Incorporated Agenda Remarks and Assumptions Business Model Company Overview Products in Development Medical Peptides NADs Inhibitors GP IIb/IIIa Inhibitor Next Steps Closing Comments The Codes for Global Success… A T C G 010101010101010 VDDI’s Global Goal To increase knowledge and commercial value in novel drug development for life-threatening indications in the areas of cardiovascular and infectious diseases by: Using the in-licensing model to fill gaps Increasing the depth in our portfolio Out-licensing to maximize the value of investments A Knowledge-driven Global Economy Pharmaceutical companies – playing the role of change agents -- must prepare for the future and adopt and support technology – biopharmaceuticals, ICT and nanotechnology. They must see themselves as active partners, rather than passive benefactors, with the stakeholders they support. If they don’t, they will get a lot poorer.* * Jianming Li, National Cancer Institute, Washington, DC; William Halal, The George Washington University, Washington, DC A 21st Century Approach VDDI’s focus is in targeted drugs (cardiovascular and infectious disease) with effective treatments aimed at smaller sets of patients. Global Biopharmaceutical Pain